Concurrent acalabrutinib, bendamustine, and rituximab in the first-line setting improved outcomes for patients with mantle cell lymphoma (MCL) relative to sequential treatment without acalabrutinib.

HealthDay News — A widely used blood pressure medication is being pulled from shelves after testing suggested some batches may contain traces of other drugs. Glenmark Pharmaceuticals has recalled ...

The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.

Findings seen for older adults experiencing gabapentinoid (gabapentin and pregabalin)-edema-loop diuretic prescribing cascade ...

LumosityRx is a prescription therapeutic app that includes 13 cognitive training games targeting key brain processes connected to attention function.

The homeopathic nasal spray is used to temporarily relieve nasal symptoms associated with cold and flu, including congestion and rhinorrhea. The recalled product, which has a lot number of 224268 and ...

Researchers assessed whether a set dose of luspatercept could be safe in treating pediatric patients with non–transfusion dependent beta-thalassemia.

Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL.

Many families with children being treated for acute lymphoblastic leukemia face household material hardship and/or income loss.

Identity disclosure to a family member or friend linked to increased risks for suicide intention, plan, attempt.

Investigators evaluated outcomes for patients with pediatric AML with and without etoposide during first-line induction treatment.

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.